Pliant Therapeutics, Inc. Stock Analysis & AI Score
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Biotechnology |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NASDAQ |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Pliant Therapeutics, Inc. (PLRX) holds an ST Score of 46.6 out of 100 (C+), with its strongest factor being Forecast (A) and its weakest Momentum (D+). Analysts rate PLRX Buy across 16 ratings with a $25.86 average price target (+22.3% vs the current $1.11).
- Strongest
- ForecastA
- Weakest
- MomentumD+
All factor grades
- ForecastA
- ValuationB-
- Financial StrengthB-
- ProfitabilityC
- GrowthC
- MomentumD+
- Piotroski2/9
Contact
PLRX stock: frequently asked questions
What is PLRX's ST Score?
Pliant Therapeutics, Inc. (PLRX) has an ST Score of 46.6 out of 100, an overall grade of C+. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is PLRX a buy, sell, or hold?
Wall Street's consensus rating on PLRX is Buy based on 16 analyst ratings. Our own ST Score grades it C+ (46.6/100). This is data, not investment advice — always do your own research.
What is PLRX's valuation grade?
Pliant Therapeutics, Inc. (PLRX) earns a valuation grade of B-, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is PLRX's growth grade?
Pliant Therapeutics, Inc. (PLRX) earns a growth grade of C, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is PLRX's profitability grade?
Pliant Therapeutics, Inc. (PLRX) earns a profitability grade of C, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is PLRX's financial strength grade?
Pliant Therapeutics, Inc. (PLRX) earns a financial strength grade of B-, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for PLRX?
The average analyst price target for Pliant Therapeutics, Inc. (PLRX) is $25.86 from 16 analysts, which is +22.3% versus the recent price of $1.11.
What is PLRX's Piotroski score?
Pliant Therapeutics, Inc. (PLRX) has a Piotroski F-Score of 2 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.